XBIO — Xenetic Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1534525 ·
Last close
$2.39
Market Cap
$5.60M
52W High
$13.93
52W Low
$1.87
ADV30
132,113
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 660,601 | — | -971,690 | -929,695 | 6,967,998 | 6,471,766 | 894,977 |
| Mar 2026 | 806,923 | — | -502,117 | -456,382 | 7,908,991 | 7,347,255 | 958,239 |
| Dec 2025 | 766,296 | — | -623,027 | -579,076 | 8,363,847 | 7,883,632 | 968,025 |
| Sep 2025 | 1,026,957 | — | -544,734 | -509,940 | 5,067,960 | 4,121,599 | 1,111,775 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,821,136
Investing CF
—
Financing CF
—
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.57
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-200,331,713
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-2,394,290
Pretax Income TTM
$-2,234,101
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$3,260,777
EBITDA
—
Free Cash Flow
$-1,174,761
Enterprise Value
$2,666,640
Total Cash
$6,471,766
Total Debt
$0
Shares Out
2,343,181
Trailing EPS
$-1.15
Book Value
$3.23
ROE
-47.0%
ROA
-26.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,976,411 | -2,834,582 | -2,680,860 | 8,363,847 | 968,025 | 7,395,822 | -2,286,651 |
| Dec 2024 | 2,500,284 | -4,204,428 | -3,960,275 | 6,901,443 | 894,263 | 6,007,180 | -2,817,478 |
| Dec 2023 | 2,539,986 | -4,515,715 | -4,134,578 | 10,605,226 | 809,585 | 9,795,641 | -4,114,219 |
| Dec 2022 | 1,706,925 | -6,717,908 | -6,552,353 | 14,720,290 | 1,073,156 | 13,647,134 | -4,646,765 |
TTM Snapshot
Revenues TTM
$35,967
NetIncome TTM
$-29,264
OpCashFlow TTM
$0
Assets (Latest)
$222,500
Forward EPS
$-0.66
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INBP | INTEGRATED BIOPHARMA INC | $5.59M | $0.18 | — |
| DRMA | Dermata Therapeutics, Inc. | $5.65M | $1.14 | — |
| XTLB | XTL BIOPHARMACEUTICALS LTD | $5.41M | $2.20 | — |
| KAPA | Kairos Pharma, LTD. | $5.82M | $1.72 | — |
| ACXP | Acurx Pharmaceuticals, Inc. | $5.84M | $1.36 | — |
News headlines (Yahoo Finance, 1h cache)
Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake
2026-09-16 14:30 · Yahoo
Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition
2026-09-16 14:28 · Yahoo
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics
2026-09-16 11:00 · Yahoo
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination
2026-06-04 12:40 · Yahoo
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
2026-05-13 12:05 · Yahoo
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
2026-04-22 13:00 · Yahoo
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
2026-06-01 13:02 · Yahoo
Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
2026-08-07 12:35 · Yahoo
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
2026-03-13 12:00 · Yahoo
Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting
2025-12-11 22:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.